Rheumatoid arthritis: A new challenge in coming era

Mini-Reviews in Medicinal Chemistry

Volumn 10, Issue 2, 2010, Pages 98-107

  Rewatkar, Prarthana V ^a   Kokil, Ganesh R ^b   Verma, Arunima ^c   Thareja, Suresh ^c  

^a STES's Smt Kashibai Navale College of Pharmacy   (India)

^b Sinhgad Institute of Pharmaceutical Sciences   (India)

^c GVM College of Pharmacy   (India)

Author keywords

Arthritis; Diagnosis; Dmards; Nsaids; Nutraceuticals; Pathophysiology; Ra; Tnf modifiers

Indexed keywords

ABATACEPT; ACETYLSALICYLIC ACID; ANTINUCLEAR ANTIBODY; CERTOLIZUMAB PEGOL; CP 550; CP 690; CYCLOSPORIN; DEXIBUPROFEN; DICLOFENAC; FLURBIPROFEN; GOLIMUMAB; HLA DR1 ANTIGEN; HLA DR4 ANTIGEN; HYDROXYCHLOROQUINE; IBUPROFEN; KETOPROFEN; LEFLUNOMIDE; METHOTREXATE; NAPROXEN; OCRELIZUMAB; OFATUMUMAB; PENICILLAMINE; REBAMIPIDE; RHEUMATOID FACTOR; RITUXIMAB; SALAZOSULFAPYRIDINE; TETRACYCLINE; THALIDOMIDE; TOCILIZUMAB; TOFACITINIB; TOLMETIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANALGESIC AGENT; ANTIRHEUMATIC AGENT; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; MONOCLONAL ANTIBODY; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTHROPATHY; ARTICULAR CARTILAGE; BIRTH DEFECT; BLEEDING; BLISTER; CLINICAL TRIAL (TOPIC); CONNECTIVE TISSUE; DIARRHEA; ERYTHROCYTE SEDIMENTATION RATE; EYE DISEASE; FEVER; GASTROINTESTINAL DISEASE; GINGIVA PAIN; HAIR LOSS; HEADACHE; HERPES ZOSTER; HUMAN; HYPERTENSION; INFLAMMATION; KIDNEY INJURY; LIVER INJURY; MOUTH PAIN; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NUTRIENT SUPPLY; OSTEOPOROSIS; PHOTOSENSITIVITY; PNEUMONIA; RASH; RETINA INJURY; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; ULCER; CHEMISTRY; PATHOPHYSIOLOGY;

ADRENAL CORTEX HORMONES; ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIPSYCHOTIC AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYCLOOXYGENASE 2 INHIBITORS; HUMANS;

EID: 77954732517     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955710791185136     Document Type: Review

References (89)

1. Mckenzie, L. S.; Horsburgh, B. A.; Ghosh, P.; Taylor, T. K. F.; Osteoarthrosis: uncertain rationale for anti-inflammatory drug therapy. Lancet, 1976, 1, 908-909.
2. Scott, J. C.; Hochberg, M. C. Arthritis and other musculoskeletal diseases, American Public Health Association, Washington D.C. 1998, pp. 465-90.
3. Granholm, J. M. Department of Community Health MIDCH, fact sheet, Jan 2007.
4. Hirsch, R.; Lin J-P.; Scott Jr, W. W.; Ma, L. D.; Pillemer, S. R.; Kastner, D. L. Rheumatoid arthritis in the Pima Indians: The intersection of epidemiologic, demographic, and genealogic data Arthritis. Rheum., 1998, 41, 1464-69.
5. Silman, A.; Bankhead, C.; Rowlinson, B. Do new cases of rheumatoid arthritis cluster in time or in space? Int. J. Epidemiol., 1997, 26, 628-34.
6. El-Gabalawy, H. S.; Goldbach-Mansky, R.; Smith, D. Association of HLA alleles and clinical features in patients with synovitis of recent onset Arthritis Rheum., 1999, 42, 1696-1705.
7. Fabio, A.; Drive, S. W.; Suite, A. The Art of Getting Well, The Rheumatoid Disease Foundation, 1988, Vol. 2, pp. 6-12.
8. Martin, R. H. The role of nutrition and diet in Rhumatoid arthritis. Proc. Nutr. Soc., 1998, 57, 231-4.
9. Fabio, A.; Drive, S. W.; Suite, A. Rheumatoid Diseases Cured at Last, The Rheumatoid Disease Foundation, 1985, Vol. 2, pp. 120-132.
10. Walker, J. G.; Littlejohn, G. O.; McCurray, N. E.; Cutolo, M. Stress system response and rheumatoid arthritis: a multilevel approach. Rheumatology, 1999, 38,1050-1057.
11. Biwaters, E. G. L. Lesions of bursae, tendons and tendon sheaths. Clin. Rheum. Dis., 1979, 5, 883-925.
12. Vollertsen, R. S.; Conn, D. L. Vasculitis associated with rheumatoid arthritis. Rheum. Dis. Clin. North. Am., 1990, 16, 445-61.
13. McCune, W. J.; Schiller, A. L.; Dynesius-Trentham, R. A.; Trentham, D. E. Type II collageninduced auricular chondritis. Arthritis Rheum., 1982, 25, 266-73.
14. Gonzalez-Gay, M. A.; Garcia-Porrua, C.; Hajeer, A. H. Corticotropin-releasing hormone promoter polymorphisms in patients with rheumatoid arthritis from northwest Spain. Arthritis Rheum., 2002, 31, 355-60.
15. Shevach, E. M. Regulatory/suppressor T cells in health and disease Arthritis Rheum., 2004, 50, 2721-24.
16. Tang, Q.; Bluestone, J. A. Regulatory T-cell physiology and application to treat autoimmunity Immunol. Rev., 2006, 212, 217-37.
17. Firestein, G. S. Evolving concepts of rheumatoid arthritis Nature, 2003, 423, 356-61.
18. Mcinnes, I. B.; Schett, G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol., 2007, 7(6), 429-42.
19. Pettit, A. R.; Walsh, N.; Manning, C. C.; Goldring, S. R.; Gravallese, E. M. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis. Rheumatology, 2006, 45(9), 1068-76.
20. Remmers, E. F.; Sano, H.; Wilder, R. L. Coexpression of phosphotyrosine-containing proteins, platelet-derived growth factor-B, and fibroblast growth factor-1 in situ in synovial tissues of patients with rheumatoid arthritis and Lewis rats with adjuvant or streptococcal cell wall arthritis. J. Clin. Invest., 1993, 91(2), 553-65.
21. Yamanishi, Y.; Firestein, G. S. Pathogenesis of rheumatoid arthritis: the role of synoviocytes. Rheum. Dis. Clin. North. Am. 2001, 27, 355-371.
22. Kong, Y. Y.; Yoshida, H.; Sarosi, I.; Tan, H. L.; Timms, E.; Capparelli, C. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis Nature, 1999, 397, 315-23.
23. Smolen, J. S.; Steiner, G. Therapeutic strategies for rheumatoid arthritis. Nat. Rev. Drug. Discov. 2003, 2, 473-88.
24. Perneger, T. V.; Whelton, P. K.; Klag, M. J. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N. Engl. J. Med., 1994, 331, 1675-79.
25. Case, J. P. Folate, homocysteine, and cobalamin status in patients with rheumatoid arthritis treated with methotrexate, and the effect of low dose folic acid supplement. Am. J. Thr., 2001, 8, 123-43.
26. Jones, R. H.; Tait, C. L. Gastrointestinal side-effects of NSAIDs in the community. Br. J. Clin. Pract. 1995, 49(2), 67-70.
27. Gillis, J. C.; Brogden, R. N. NSAIDs: A reappraisal of its pharmacodynamic and pharmacokinetic properties, therapeutic use and side effects in pain management for rheumatoid arthritis, 6th ed. 1997, Vol. 3, p.139-188.
28. MacLeod, D. B.; Swanson, R. A new approach to chronic pain in the ED. Am. J. Emerg. Med. 1996, 14, 323-326.
29. Whelton A.; Maurath, C. J.; Verburg, K. M.; Geis, G. S. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am. J. Ther., 2000, 7, 159-75.
30. Kehlet, H.; Werner, M. U. Role of paracetamol in acute pain management. Drugs, 2003, 63, 15-22.
31. Stein, C.; Schafer, M.; Machelska, H. Why is morphine not the ultimate analgesic and what can be done to improve it? J. Pain 2000, 1, 51-6.
32. Juni, P.; Rutjes, A.; Dieppe, P. Are selective COX-2 inhibitors superior to traditional NSAIDs? Br. Med. J., 2002, 324, 1287-8.
33. Simon, L.; Lanza, F.; Lipsky, P.; Hubbard, R.; Talwalker, S.; Schwartz, B. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor. Arthritis Rheum., 1998, 41, 1591-1602.
34. Kramer, B. K.; Kammerl, M. C.; Komhoff, M. Renal Cyclooxygenase-2 (Cox-2) Kidney. Blood Press. Res., 2004, 27, 43-62.
35. Kremer, J. M. Rational Use of New and Existing Disease-Modifying Agents in Rheumatoid Arthritis Ann. Intern. Med., 2001, 134, 695-706.
36. Kremer, J. M.; Weinblatt, M. E. Safty, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: Folloup after a mean of 13.3 years Arthritis Rheum., 1997, 40, 984-95.
37. Johnston, A.; Gudjonsson, J. E.; Sigmundsdottir, H.; Ludviksson, B. R.; Valdimarsson, H. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin. Immunol., 2005, 4, 154-63.
38. O'Dell J. Conventional DMARD options for patients with a suboptimal response to methotrexate. J. Rheumatol. Suppl., 2001, 62, 21-26.
39. Kremer, J. M,; Kaye, G. I.; Kaye, N. W.; Ishak, K. G.; Axiotis, C. A. Light and electron microscopic analysis of sequential liver biopsy samples from rheumatoid arthritis patients receiving longterm methotrexate therapy. Arthritis Rheum., 1995, 38, 1194-1203.
40. Wolfe, F.; Hawley, D. J.; Cathey, M. A. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J. Rheumatol., 1990, 17, 994-1002.
41. Emery P. Disease modification in rheumatoid arthritis with leflunomide. Scand J. Rheumatol., 1999, 112 (l), 9-14.
42. Kalden, J. R.; Schattenkirchner, M.; Sorensen, H.; Emery, P.; Deighton, C.; Rozman, B. Arthritis Rheum., 2003, 48, 1513-20.
43. Dell, J. R.; Haire, C. E.; Erikson, N.; Drymalski, W.; Palmer, W.; Eckhoff, P. J. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications N. Engl. J. Med., 1996, 334, 1287-91.
44. Paton, N. I.; Aboulhab, J.; Karim, F. Hydroxychloroquine, hydroxycarbamide, and didanosine as economic treatment for HIV-1. Lancet, 2002, 359, 1667-68.
45. The HERA Study Group. A randomized trial of hydroxychloroquine in early rheumatoid arthritis. Am. J. Med., 1995, 98, 156-68.
46. Wolfe F, Cush JJ, Dell JR, Kavanaugh A, Kremer JM, Lane NE, Moreland LW, Paulus HE, Pincus T, Russell AS, Wilskie KR. Consensus recommendations for the assessment and treatment of rheumatoid arthritis. J. Rheumatol., 2001, 28, 1423-1430.
47. Suissa S, Ernst P, Kezouh A, Bitton A, Hudson M. Newer Diseasemodifying anti-rheumatic drug and the risk of serious hepatic adverse events in patients with rheumatoid arthritis. Am. J. Med., 2004, 117, 87-92.
48. Saag KG, Criswell LA, Sems KM, et al. Low-dose corticosteroids in rheumatoid arthritis. A meta-analysis of their moderate-term effectiveness. Arthritis Rheum., 1996, 39, 1818-1825.
49. Van Everdingen, A.; Jacobs, J.; Van Reesema, D. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo controlled clinical trial. Ann. Intern. Med., 2002, 136, 1-12.
50. Old, L. J. Tumor necrosis factor. Sei. Am., 1988, 258, 59-75.
51. Aslanidis, S.; Pyrpasopoulou, A.; Douma, S.; Triantafyllou, A. Tumor necrosis factor-a antagonist-induced psoriasis: yet another paradox in medicine, Clin. Rheumatol., 2008, 27(3), 377-380
52. Criscione, L. G.; St Clair, E. W. Tumor necrosis factor-alpha antagonists for the treatment of rheumatic disease. Curr. Opin. Rheumatol., 2002, 14, 204-11.
53. Maini, R. N.; Breedveld, F. C.; Kalden, J. R. Anaphylactic reaction to infliximab in two rheumatoid arthritis patients who had previously received infliximab and resumed. Arthritis Rheum., 1998, 41, 1552-63.
54. Maini, R.; St Clair, E. W.; Breedveld, F.; Furst, D.; Kalden, J.; Weisman, M.; Smolen, J.; Emery, P.; Harriman, G.; Feldmann, M.; Lipsky, P. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet, 1999, 354(9194), 1932-9.
55. Moreland, L. W.; Baumgartner, S. W.; Schiff, M. H. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med., 1997, 337,141-47.
56. Davis Jr., J. C.; Huang, F.; Maksymowych, W. Blocking tumor necrosis factor in ankylosing spondylitis. Rheum. Dis. Clin. North. Am., 2003, 29(3), 481-94.
57. Dinarello, C. A. Role of IL-1-mediated inflammation in tumor angiogenesis. Blood., 1996, 87, 2095-2147.
58. Irigoyen, P. I.; Olsen, J.; Hom, C.; Ilowite, N. T. Treatment of systemic juvenile rheumatoid arthritis with anakinra. Arthritis. Rheum. 2004, 50, S437.
59. Dushyant, M. D; Huston, K.; Kwasind, M. D. IL-1 inhibition with anakinra in a patient with refractory gout. J. Clin. Rheumatol. 2009, 15(7), 366
60. Cohen, S; Hurd, E.; Cush, J. Efficacy of biologicals in the treatment of rheumatoid arthritis. Arthritis. Rheum., 2002, 46, 614-24.
61. Nisar, M.; Carlisle, L.; Amos, R. S. Methotrexate and Sulphasalazine as combination therapy in rheumatoid arthritis. Br. J. Rheumatol., 1994, 33, 651-4.
62. Kremer JM. Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann. Intern. Med., 2001, 134, 695-706.
63. Jessop, J. D.; O'Sullivan, M. M.; Lewis, P. A. A long-term fiveyear randomized controlled trial of hydroxychloroquine, sodium aurothiomalate, auranofin and penicillamine in the treatment of patients with rheumatoid arthritis. Br. J. Rheumatol., 1998, 37, 992-1002.
64. Grindulis, K. A.; McConkey, B. Outcome of attempts to treat rheumatoid arthritis with gold, penicillamine, sulphasalazine, or dapsone. Ann. Rheum. Dis., 1984, 43, 398-401.
65. Gutierrez-Rodriguez, O.; Starusta-Bacal, P.; Gutierrez-Montes, O. Treatment of rheumatoid arthritis: the thalidomide experience. J. Rheumatol., 1989, 16, 158-63.
66. Rao, U. R. K.; Naidu, M. U. R.; Kumar, T. R. Comparison of Phenytoin with Auranofin and Chloroquine in Rheumatoid Arthritis-A Double Blind Study. J. Rheumatol., 1995, 22, 1235-40.
67. Kaisa, M.; Anthony, D.; Booth, M. D.; Frances, C.; Sharon, M. L.; Wallace, B. A.; John Brown, D. M.; Carmel, M. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J. Am. Coll. Cardiol., 2007, 50(9), 852-58.
68. Fraser, D.; Thoen, J.; Djoseland, O.; Forre, O.; Kjeldsen-Kragh, J. Serum levels of interleukin-6 and dehydroepiandrosterone sulphate in response to either fasting or a ketogenic diet in rheumatoid arthritis patients. Clin. Exp. Rheumatol., 2000, 18, 357-62.
69. van-Vollenhoven, R. F.; Engleman, E. G.; McGuire, J. L. An open study of dehydroepiandrosterone in systemic lupus erythematosus. Arthritis Rheum., 1994, 37(9), 1305-1310.
70. Alvaro-Gracia, J. M. Licofelone-clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis. Rheumatology, 2004, 43(1), i21-i25.
71. Walker, J S.; Howlett C. R.; Nayanar V. Anti-inflammatory effects of kappa-opioids in adjuvant arthritis. Life Sci., 1995, 57(4), 371-78.
72. Bruyere, O.; Pavelka, K.; Rovati, L. C.; Deroisy, R.; Olejarova, M.; Gatterova, J.; Giacovelli, G.; Reginster, J. Y. Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. Menopause, 2004, 11(2), 138-43.
73. Bartolucci, C.; Cellai, L.; Corradini, C.; Corradini, D.; Lamba, D.; Velona, I. Chondroprotective action of chondroitin sulfate: competitive action of chondroitin sulfate on the digestion of hyaluronan by bovine testicular hyaluronidase. Int. J. Tissue React., 1991, 13(6), 311-17.
74. Chou, M. M.; Vergnolle, N.; McDougall, J. J.; Wallace, J. L.; Marty, S.; Teskey, V.; Buret, A. G. Effects of chondroitin and glucosamine sulfate in a dietary bar formulation on inflammation, interleukin-1ss, matrix metalloprotease-9, and cartilage damage in arthritis. Exp. Biol. Med., 2005, 230(4), 255-62.
75. Parcell, S. Sulfur in human nutrition and applications in medicine. Altern. Med. Rev., 2002, 7(1), 22-44.
76. Stephensen, C. B. Fish Oil and Inflammatory Disease: Is Asthma the Next Target for n-3 Fatty Acid Supplements? Nutr. Rev., 2004, 62(12), 486-89.
77. Tanimoto, K.; Ohno, S.; Fujimoto, K.; Honda, K.; Ijuin, C.; Tanaka, N.; Doi, T.; Nakahara, M.; Tanne, K. Proinflammatory cytokines regulate the gene expression of hyaluronic acid synthetase in cultured rabbit synovial membrane cells. Tissue Res., 2001, 42(3), 187-95.
78. Nonaka, T.; Kikuchi, H.; Ikeda, T.; Okamoto, Y.; Hamanishi, C.; Tanaka, S. Hyaluronic acid inhibits the expression of u-PA, PAI-1, and u-PAR in human synovial fibroblasts of osteoarthritis and rheumatoid arthritis. J. Rheumatol., 2000, 27(4), 997-1004.
79. Cazzola, M.; Artivalle, M.; Sazzi-Puttini, P. Oral type II collagen in the treatment of rheumatoid arthritis. A six-month double blind placebo-controlled study. Clin. Exp. Rheum., 2000, 18, 571-78.
80. Barnett, M. L.; Kremmer, J. M.; St. Clair, E. W. Treatment of rheumatoid arthritis with oral type II collagen: results of multicenter, double-blind, placebo-controlled trail. Arthritis Rheum., 1998, 41, 290-97.
81. Burton, C.; Kaczmarski, R.; Jan-Mohamed, R. Interstitial pneumonitis related to rituximab therapy. N. Engl. J. Med. 2003, 348(26), 2690-91.
82. Magistrelli, G.; Caron, G.; Gauchat, J. F.; Jeannin, P.; Bonnefoy, J. Y.; Delneste, Y. Identification of an alternatively spliced variant of human CD86 mRNA. Biochem. Biophys. Res. Commun. 2001, 280(5), 1211-15.
83. Keystone, E. C.; Genovese, M. C.; Klareskog, L.; Hsia, E. C.; Hall, S. T. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the go-forward Study. Ann. Rheum. Dis., 2009, 68, 789-96.
84. Woo, P.; Wilkinson, N.; Prieur, A. M.; Southwood, T.; Leone, V.; Livermore, P.; Wythe, H,; Thomson, D.; Kishimoto, T. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis. Res. Ther., 2005, 7(6), R1281-8.
85. Kausar, F.; Mustafa, K.; Sweis, G.; Sawaqed, R.; Alawneh K.; Salloum, R.; Badaracco, M.; Niewold, T. B.; Sweiss N. J. Ocrelizumab: a step forward in the evolution of B-cell therapy. Expet. Opin. Biol. Ther., 2009, 9 (7), 889-95.
86. Coiffier, B.; Lepretre, S.; Pedersen, L. M.; Gadeberg, O.; Fredriksen, H.; van Oers, M. H.; Wooldridge, J.; Kloczko, J.; Holowiecki, J.; Hellmann, A.; Walewski, J.; Flensburg, M.; Petersen, J.; Robak, T. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood, 2008, 111(3), 1094-100.
87. Arakawa, T.; Watanabe, T.; Fukuda, T.; Yamasaki, K.; Kobayashi, K. Rebamipide, novel prostaglandin-inducer accelerates healing and reduces relapse of acetic acid-induced rat gastric ulcer. Comparison with cimetidine. Dig. Dis. Sci., 1995, 40 (11), 2469-72.
88. Rose-John, S.; Schooltink, H. CDP-870. Celltech/Pfizer. Curr. Opin. Investig. Drugs, 2003, 4(5), 588-92.
89. Lawendy, N.; Krishnaswami, S.; Wang, R.; Gruben, D.; Cannon, C.; Swan, S.; Chan, G. Effect of CP-690,550, an Orally Active Janus Kinase Inhibitor, on Renal Function in Healthy Adult Volunteers. J. Clin. Pharmacol., 2009, 49, 423-429.